Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$8.27 USD
+0.10 (1.22%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $8.46 +0.19 (2.30%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.27 USD
+0.10 (1.22%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $8.46 +0.19 (2.30%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Zacks News
Horizon (HZNP) Marketed Drugs Aid Growth, Stiff Rivalry a Woe
by Zacks Equity Research
Horizon's (HZNP) portfolio of marketed drugs, including Tepezza and Krystexxa, aid growth. The company is also working on the label expansion of its drugs. However, stiff competition remains a woe.
Novo (NVO) Posts Positive Data From Diabetes Study on CagriSema
by Zacks Equity Research
Novo Nordisk (NVO) completes the phase II study evaluating CagriSema, a combination of semaglutide and cagrilintide for treating type II diabetes.
Axsome (AXSM) Soars on FDA Nod for Depression Drug, Auvelity
by Zacks Equity Research
The FDA approves Axsome's (AXSM) Auvelity extended-release tablets for the treatment of major depressive disorder in adults. This becomes the first approved product for the company. Shares rise.
Blueprint Medicines' (BPMC) Ayvakit Meets Goal in PIONEER Study
by Zacks Equity Research
Blueprint Medicines (BPMC) posts top-line data from part 2 of the PIONEER study evaluating Ayvakit in patients with non-advanced systemic mastocytosis. Shares down.
Horizon (HZNP) Inks Collaboration Deal with Q32 Bio for ADX-914
by Zacks Equity Research
Horizon (HZNP) enters into a collaboration and option agreement with Q32 Bio to develop the latter's ADX-914 for treating autoimmune diseases.
Does Atara Biotherapeutics (ATRA) Have the Potential to Rally 204% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Atara Biotherapeutics (ATRA) points to a 204.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe
by Zacks Equity Research
Seagen (SGEN) focuses on improving sales of its marketed drugs approved for different types of cancer indications. Stiff competition in the market remains a woe.
Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 65.93% and 483.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Immunovant (IMVT) Loss Narrows in Q1, Focus on Batoclimab
by Zacks Equity Research
Immunovant's (IMVT) earnings beat estimates in the fiscal first quarter ended on Jun 30, 2022. The company is evaluating batoclimab in a pivotal study for treating myasthenia gravis.
Deciphera (DCPH) Loss Narrows in Q2, Qinlock Drive Revenues
by Zacks Equity Research
Deciphera (DCPH) reports a narrower-than-expected loss in the second quarter of 2022 while revenues beat estimates. Shares rise.
Calyxt (CLXT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Calyxt (CLXT) delivered earnings and revenue surprises of 6.67% and 36.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Editas' (EDIT) Loss Narrows in Q2, Revenues Trump Estimates
by Zacks Equity Research
Editas (EDIT) reports a narrower-than-expected loss in the second quarter of 2022 while its revenues beat estimates. Focus remains on the lead candidate, EDIT-101.
Novo Nordisk's (NVO) Q2 Earnings Miss, Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) missed estimates for earnings in the second quarter of 2022 while revenues beat the same, driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
Horizon (HZNP) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Horizon's (HZNP) earnings and revenues lag estimates in the second quarter of 2022. The company lowers full-year revenue guidance for 2022. Shares were down in pre-market trading.
After Plunging 65.7% in 4 Weeks, Here's Why the Trend Might Reverse for Atara Biotherapeutics (ATRA)
by Zacks Equity Research
Atara Biotherapeutics (ATRA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Dr. Reddy's (RDY) Q1 Earnings Increase Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and sales increase year over year in first-quarter fiscal 2023.
Atara Biotherapeutics (ATRA) Moves 17% Higher: Will This Strength Last?
by Zacks Equity Research
Atara Biotherapeutics (ATRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 11.22% and 11.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Alkermes (ALKS) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 1,100% and 6.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Atara Biotherapeutics (ATRA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Atara Biotherapeutics (ATRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -60% and 84.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Atara Biotherapeutics (ATRA) This Earnings Season?
by Zacks Equity Research
Atara Biotherapeutics (ATRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics
by Zacks Equity Research
Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.
Biotech Stock Roundup: SAGE, ATRA Down on Study Updates, AGIO Drug Approval & More
by Zacks Equity Research
Updates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week.